A national study has, for the first time, linked the shortage of a number cancer drugs to a higher rate of relapse among children, teenagers and young adults with Hodgkin lymphoma. The patients were enrolled in a national clinical trial led by researchers at the St. Jude Children's Research Hospital, Memphis, TN, USA.

Estimated two-year cancer-free survival for patients enrolled in the study fell from 88-75% after the drug…

New research presented at the 53rd Annual Meeting of the American Society of Hematology being held in San Diengo, CA, December 10 - 13, concludes that patients with limited-stage Hodgkin lymphoma treated with a standard chemotherapy regimen have better overall survival rates compared with those receiving a radiation-based treatment.



Patients with limited-stage Hodgkin lymphoma (HL) are often treated with…

Hematological cancers such as lymphoma and myeloma are both malignant diseases arising from lymphocytes, a subset of blood cells, and commonly involve lymph nodes and the bone marrow.



One of these cancers, multiple myeloma is a hematologic cancer, or cancer of the blood, that starts in plasma cells, a type of white blood cell that make antibodies and work with the immune system to help protect the body from germs and other harmful…

HIV-infected patients are at increased risk for cancer as a result of both their impaired immune system and lifestyle factors, such as smoking, according to researchers at Kaiser Permanente.



The study, which appears in the current issue of Cancer Epidemiology, Biomarkers and Prevention, is among the first to directly compare the…

First, findings from preclinical studies showed that treatment with a novel oral agent, PLX3397, a selective kinase inhibitor that down-modulates macrophages, microglia, osteoclasts and mast cells, re-programmed the tumor microenvironment, supporting further development of this single agent treatment for certain cancers and malignancies such as prostate cancer. Is scientific findings was presented during the AACR-NCI- EORTC International Conference on Molecular Targets and Cancer…

Six out of nine pediatric patients with relapsed or refractory Hodgkin lymphoma (HL) (n=5)or systemic anaplastic large cell lymphoma (sALCL) (n=4)achieved complete remission (CR) in multicenter phase I and phase II trials of Brentuximab Vedotin ( SGN-35 and previously called cAC10-vcMMAE; now marketed as Adcetris™ by Millennium: The…

European Medicines Agency (EMA) has accepted the filing of the Marketing Authorization Application (MAA) for brentuximab vedotin (Adcetris™, Takeda Pharmaceutical and Millennium: The Takeda Oncology Company) for the treatment of relapsed or refractory Hodgkin lymphoma (HL) and relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). The Marketing Authorization Application was filed by Takeda Global Research &…

While 70 to 80% of all newly diagnosed patients with adult Hodgkin lymphoma are typically cured with combination chemotherapy of three or four agents together, there still is a significant number of patients whose disease progresses after initial induction chemotherapy. For these patients, treatment options include additional courses of the same or different chemotherapy regimens followed by an autologous stem cell transplant. However, for patients whose disease returns after an…